Immunoglobulin, Complement, and Immune Complex Levels During a Migraine Attack

Moore, Terry L.; Ryan, Robert E.; Pohl, Douglas A.; Roodman, Stanford T.

doi:10.1111/j.1526-4610.1980.hed2001009.x

Cited by 23 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of PGR has been reported in migraine [Colson et al, 2005] and more recently in migraine associated vertigo syndrome [Lee et al, 2007]. Cytokines are part of the acute and chronic inflammatory responses of the central nervous system [Moore et al, 1980;Munno et al, 1998]. TNFa is a proinflammatory cytokine that has been shown to play a role in nociception [Sachs et al, 2002;Wagner and Myers, 1996].…”

Section: Other Genesmentioning

confidence: 99%

Migraine genetics and prospects for pharmacotherapy

Colson

Fernandez

Griffiths

2007

Drug Development Research

View full text Add to dashboard Cite

Migraine is a common complex neurological disorder with a well-known but poorly characterized genetic liability. The search for migraine susceptibility genes has been the focus of intense research. It is now believed that common migraine is not a single gene disorder, but attributable to several potentially interacting genetic variants. These variants may differ in each sufferer and interact with environmental factors to set the individual migraine threshold. This genetic liability may play an important role in the clinical heterogeneity seen in migraine and also in the variability of treatment response. This review will look at genetic loci implicated in migraine to date and consider their current or prospective role in migraine therapy. To elucidate the complex nature of migraine genetic liability, approaches that consider detailed endophenotypic profiles that encompass treatment response may provide much more relevant information than simple end diagnosis. Drug Dev Res 68: 282-293, 2007. r 2007 Wiley-Liss, Inc.

show abstract

Section: Other Genesmentioning

confidence: 99%

Migraine genetics and prospects for pharmacotherapy

Colson

Fernandez

Griffiths

2007

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…Recent studies have attempted to identify specific immune molecules, eg, complement 6 and interleukins 7 as relevant soluble mediators of the immunologic deficit predisposing to migraine 8‐10 …”

mentioning

confidence: 99%

Immunological Aspects in Migraine: Increase of IL‐10 Plasma Levels During Attack

et al. 2001

View full text Add to dashboard Cite

In the present study, 23 patients with migraine without aura were monitored during a migraine attack. Plasma levels of interleukin (IL)-4, IL-5, IL-10, and interferon-gamma were measured by enzyme-linked immunosorbent assay techniques. Interestingly, we observed low to undetectable IL-5 and IL-4 levels, whereas high IL-10 levels were seen in 52.2% of the patients. Interferon-gamma plasma levels were undetectable in all patients. After treatment with sumatriptan, 10 patients showed a subsequent decrease in IL-10 and an increase in both IL-4 and IL-5 plasma levels. Although these findings are derived from a limited number of patients, the apparent return to the IL-4 and IL-5 cytokine profile observed during the interictal period leads us to speculate that a preferential enhancement of TH2-type cytokine production may contribute to the pathogenesis of migraine.

show abstract

“…The pathogenesis of migraine is still largely unknown. A large number of immunological abnormalities have been described in the plasma, urine, and cerebrospinal fluid of patients with migraine, supporting a possible role for the immune system 1‐3 . At present, however, it is unknown whether these findings are specific to the disease or are in fact only a consequence of the headache attacks 4…”

mentioning

confidence: 99%